Skip to content
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Menu
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Subscribe
Search
Close this search box.
Read more about the article Sunstone Therapies Announces Expansion of Innovative Dyad Study

Sunstone Therapies Announces Expansion of Innovative Dyad Study

  • Post published:October 3, 2023
  • Post category:Press Release
Read more about the article Sunstone Therapies in Collaboration with the University of Vermont Announces Publication of Study Showing Feasibility of Direct Observation of Therapeutic Connection in Psilocybin-Assisted Therapy

Sunstone Therapies in Collaboration with the University of Vermont Announces Publication of Study Showing Feasibility of Direct Observation of Therapeutic Connection in Psilocybin-Assisted Therapy

  • Post published:August 25, 2023
  • Post category:Press Release
Read more about the article Sunstone Therapies presents data at ASCO showing positive long-term follow-up results from psilocybin therapy in cancer patients with major depressive disorder (MDD)

Sunstone Therapies presents data at ASCO showing positive long-term follow-up results from psilocybin therapy in cancer patients with major depressive disorder (MDD)

  • Post published:May 26, 2023
  • Post category:Press Release
Read more about the article Sunstone Therapies to present data on the long-term efficacy of psilocybin therapy in cancer patients with major depressive disorder (MDD) at the ASCO 2023 Annual Meeting

Sunstone Therapies to present data on the long-term efficacy of psilocybin therapy in cancer patients with major depressive disorder (MDD) at the ASCO 2023 Annual Meeting

  • Post published:May 11, 2023
  • Post category:Press Release
Read more about the article Sunstone Therapies Collaborates with MAPS to Conduct Clinical Trial of MDMA-Assisted Therapy for PTSD

Sunstone Therapies Collaborates with MAPS to Conduct Clinical Trial of MDMA-Assisted Therapy for PTSD

  • Post published:September 14, 2022
  • Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More